Evidence map›Paper›PMID 38559060›Full record

ArticlebioRxiv : the preprint server for biology2024

Long-read single-cell RNA sequencing enables the study of cancer subclone-specific genotype and phenotype in chronic lymphocytic leukemia.

Gage S Black, Xiaomeng Huang, Yi Qiao, Philip Moos, Deepa Sampath, Deborah M Stephens, Jennifer A Woyach, Gabor T Marth

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Gage S BlackDepartment of Human Genetics, University of Utah, Salt Lake City, UT.ORCID 0000-0003-2086-5266
Xiaomeng HuangDepartment of Human Genetics, University of Utah, Salt Lake City, UT.
Yi QiaoDepartment of Human Genetics, University of Utah, Salt Lake City, UT.
Philip MoosDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT.
Deepa SampathDepartment of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX.
Deborah M StephensDivision of Hematology, University of North Carolina, Chapel Hill, NC.
Jennifer A WoyachThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Gabor T MarthDepartment of Human Genetics, University of Utah, Salt Lake City, UT.ORCID 0000-0003-0222-1694
University of Utah · USThe Ohio State University · USThe University of Texas MD Anderson Cancer Center · USUniversity of North Carolina at Chapel Hill · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Tolinapant efficacy in a subset of triple negative breast cancersU54CA224076 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Michael T. Lewis · 2017 to 2026
$13.5M
Targeted Therapy for Lymphoid MalignanciesR01CA177292 · NCI · OHIO STATE UNIVERSITY · PI ROGERS, KERRY ANNE, WOYACH, JENNIFER A. · 2013 to 2025
$5.3M
Monitoring tumor subclonal heterogeneity over time and spaceU24CA209999 · NCI · UNIVERSITY OF UTAH · PI MARTH, GABOR T, QUINLAN, AARON R · 2016 to 2020
$3.9M
Molecular Evaluation of Targeted Therapies in Lymphoid MalignanciesR01CA183444 · NCI · OHIO STATE UNIVERSITY · PI BYRD, JOHN C., WOYACH, JENNIFER A. · 2014 to 2018
$2.6M
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell LymphomasR50CA275929 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DEBORAH STEPHENS · 2023 to 2026
$673k
From genomics to natural language processing: A protected environment for research computing in the health scienceS10OD021644 · OD · UNIVERSITY OF UTAH · PI CHEATHAM, THOMAS E. · 2017 to 2017
$494k
NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA177292NCI NIH HHS R01 CA183444NCI NIH HHS R50 CA275929NCI NIH HHS U24 CA209999NCI NIH HHS U54 CA224076NIH HHS S10 OD021644
6 · The paper itself

Abstract

Bruton's tyrosine kinase (BTK) inhibitors are effective for the treatment of chronic lymphocytic leukemia (CLL) due to BTK's role in B cell survival and proliferation. Treatment resistance is most commonly caused by the emergence of the hallmark

Identifiers

PMID38559060
PMCPMC10979946
OpenAlexW4392910969

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.